These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27134280)

  • 1. Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study.
    Smith V; Pizzorni C; Riccieri V; Decuman S; Brusselle G; DE Pauw M; Deschepper E; Piette Y; Ruaro B; Sulli A; Vandecasteele E; Melsens K; DE Keyser F; Cutolo M
    J Rheumatol; 2016 May; 43(5):995-6. PubMed ID: 27134280
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis.
    Vilela VS; da Silva BRA; da Costa CH; Lopes AJ; Levy RA; Rufino R
    BMC Res Notes; 2018 Dec; 11(1):874. PubMed ID: 30526656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
    Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
    Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.
    Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S
    J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579
    [No Abstract]   [Full Text] [Related]  

  • 5. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis.
    Low AH; Lee P
    J Rheumatol; 2008 Nov; 35(11):2286. PubMed ID: 19004063
    [No Abstract]   [Full Text] [Related]  

  • 6. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.
    Melsens K; Vandecasteele E; Deschepper E; Badot V; Blockmans D; Brusselle G; De Langhe E; De Pauw M; Debusschere C; Decuman S; Deroo L; Houssiau F; Lenaerts J; Piette Y; Thevissen K; Vanthuyne M; Westhovens R; Wijnant S; De Keyser F; Smith V
    Acta Clin Belg; 2018 Apr; 73(2):119-125. PubMed ID: 28891418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.
    Antonopoulos I; Daoussis D; Lalioti ME; Markatseli TE; Drosos AA; Taraviras S; Andonopoulos AP; Liossis SC
    Rheumatol Int; 2019 Nov; 39(11):1889-1898. PubMed ID: 31227855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
    Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
    Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?
    Cappelli S; Bellando-Randone S; Guiducci S; Matucci-Cerinic M
    Rheumatology (Oxford); 2014 Jun; 53(6):975-87. PubMed ID: 24185765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis.
    Yalçinkaya Y; Artim Esen B; Amikishiyev S; Aliyeva N; Gül A; Öcal L; Inanç M
    Turk J Med Sci; 2023; 53(6):1704-1712. PubMed ID: 38813512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
    Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].
    Sicińska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):192-5. PubMed ID: 18942346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis.
    Rimar D; Rosner I; Slobodin G
    J Rheumatol; 2021 Feb; 48(2):304-305. PubMed ID: 33060315
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of systemic sclerosis (except pulmonary arterial hypertension)].
    Hachulla E
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S277-84. PubMed ID: 17977626
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting very early systemic sclerosis: a case-based review.
    Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Nakamura K; Yamashita T; Miura S; Saigusa R; Ichimura Y; Takahashi T; Hirabayashi M; Taniguchi T; Akamata K; Asano Y; Sato S
    Scand J Rheumatol; 2017 May; 46(3):247-252. PubMed ID: 27900875
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic sclerosis refractory disease: from the skin to the heart.
    Almeida I; Faria R; Vita P; Vasconcelos C
    Autoimmun Rev; 2011 Sep; 10(11):693-701. PubMed ID: 21575745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis and calcinosis cutis: response to rituximab.
    Poormoghim H; Andalib E; Almasi AR; Hadibigi E
    J Clin Pharm Ther; 2016 Feb; 41(1):94-6. PubMed ID: 26667314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.